BACKGROUND: Meningiomas are the most frequent primary brain tumor in adults. Evidence suggests that female sex hormones play a role in the meningioma tumorigenesis. In particular, progesterone, has a receptor (PR) that is highly expressed in the majority of grade I meningiomas. Multiple meningiomas (diffuse meningiomatosis) are less frequent, but have a higher female predominance and a higher PR expression. They are, therefore, attractive candidates for anti-PR therapy. METHODS: We treated three consecutive women with multiple meningiomas with mifepristone (RU 486). It is a synthetic steroid with high affinity for both progesterone and glucocorticoid receptors. RESULTS: The treatment was well tolerated, and we observed an important and long-lasting clinical (3/3) and radiological response (2/3) or stabilisation. All the three patients are now stable after five to nine years of treatment. CONCLUSIONS: These encouraging results strongly support a prospective clinical trial in this preselected population.
BACKGROUND:Meningiomas are the most frequent primary brain tumor in adults. Evidence suggests that female sex hormones play a role in the meningioma tumorigenesis. In particular, progesterone, has a receptor (PR) that is highly expressed in the majority of grade I meningiomas. Multiple meningiomas (diffuse meningiomatosis) are less frequent, but have a higher female predominance and a higher PR expression. They are, therefore, attractive candidates for anti-PR therapy. METHODS: We treated three consecutive women with multiple meningiomas with mifepristone (RU 486). It is a synthetic steroid with high affinity for both progesterone and glucocorticoid receptors. RESULTS: The treatment was well tolerated, and we observed an important and long-lasting clinical (3/3) and radiological response (2/3) or stabilisation. All the three patients are now stable after five to nine years of treatment. CONCLUSIONS: These encouraging results strongly support a prospective clinical trial in this preselected population.
Authors: Taylor Anne Wilson; Lei Huang; Dinesh Ramanathan; Miguel Lopez-Gonzalez; Promod Pillai; Kenneth De Los Reyes; Muhammad Kumal; Warren Boling Journal: Front Oncol Date: 2020-11-20 Impact factor: 6.244
Authors: Jessica E Sagers; Adam S Brown; Sasa Vasilijic; Rebecca M Lewis; Mehmet I Sahin; Lukas D Landegger; Roy H Perlis; Isaac S Kohane; D Bradley Welling; Chirag J Patel; Konstantina M Stankovic Journal: Sci Rep Date: 2018-04-03 Impact factor: 4.379
Authors: Monserrat Llaguno-Munive; Sebastián León-Zetina; Inés Vazquez-Lopez; María Del Pilar Ramos-Godinez; Luis A Medina; Patricia Garcia-Lopez Journal: Front Oncol Date: 2020-10-05 Impact factor: 6.244